As GLP-1 medications such as Ozempic, Mounjaro and Wegovy rise in popularity, so do concerns over their side effects.

The FDA has determined that the nationwide shortage of semaglutide injection, used for both diabetes and weight loss, is resolved after more than two years of limited availability due to high demand.

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration said on Friday.

The Food and Drug Administration said on Friday that the shortage of semaglutide injection products, such as Novo Nordisk's Wegovy, has been resolved. FDA's update led to renewed uncertainty for a ...

The FDA has removed semaglutide from its drug shortage list after the agency determined the current supply of the drug can ...

The semaglutide shortage has officially ended in the US—which means the GLP-1 drug industry is about to undergo massive ...

Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...

Two Omaha women lost more than 300 lbs. combined with injections of a GLP-1 drug, which are used increasingly for weight loss ...

A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.

Sue Myerscough, 72, from East Morton, near Keighley, used to weigh 19 stone before taking part on the type 2 diabetes ...

A new study adds to a growing body of evidence that semaglutide has benefits other than weight loss or controlling diabetes.

Weight-loss drugs helped Dimpy Kapoor shed 15 kg and reclaim her life. Ozempic and Mounjaro are a lifeline for diabetics and ...